Characteristics of AML patients
| Patient no. . | FAB classification . | Treatment . | Remission . |
|---|---|---|---|
| 1 | M2 | Ara-C, ida, amsa, asct | CR |
| 2 | M2 | Ara-C, ida, amsa, etop, mito | PR |
| 3 | M5 | Ara-C, ida, amsa, etop, mito | CR |
| 4 | M0 | Ara-C, ida, amsa, asct | CR |
| 5 | M5 | Ara-C, ida, amsa, etop, mito | CR |
| 6 | M1 | Ara-C, ida, amsa, asct | NR |
| 7 | M5 | Ara-C, dauno, etop, mito | CR |
| 8 | M3 | Ara-C, ida, amsa, etop, mito | CR |
| 9 | M2 | Ara-C, ida, amsa, asct | PR |
| 10 | M4 | Ara-C, ida, amsa, etop, mito | CR |
| 11 | M1 | Ara-C, ida, etop, mito | CR |
| 12 | M2 | Ara-C, ida, amsa, asct | CR |
| 13 | M2 | Ara-C, dauno, amsa, etop, mito | CR |
| 14 | M2 | Ara-C, ida, amsa, asct | CR |
| 15 | M4 | Ara-C, ida, amsa, etop, mito | CR |
| 16 | M2 | Ara-C, dauno, amsa, etop, mito | PR |
| 17 | M2 | Ara-C, etop, mito | CR |
| 18 | M4 | Ara-C, dauno, asct | CR |
| 19 | M2 | Ara-C, dauno, amsa, asct | CR |
| 20 | M0 | Ara-C, dauno, amsa, asct | PR |
| Patient no. . | FAB classification . | Treatment . | Remission . |
|---|---|---|---|
| 1 | M2 | Ara-C, ida, amsa, asct | CR |
| 2 | M2 | Ara-C, ida, amsa, etop, mito | PR |
| 3 | M5 | Ara-C, ida, amsa, etop, mito | CR |
| 4 | M0 | Ara-C, ida, amsa, asct | CR |
| 5 | M5 | Ara-C, ida, amsa, etop, mito | CR |
| 6 | M1 | Ara-C, ida, amsa, asct | NR |
| 7 | M5 | Ara-C, dauno, etop, mito | CR |
| 8 | M3 | Ara-C, ida, amsa, etop, mito | CR |
| 9 | M2 | Ara-C, ida, amsa, asct | PR |
| 10 | M4 | Ara-C, ida, amsa, etop, mito | CR |
| 11 | M1 | Ara-C, ida, etop, mito | CR |
| 12 | M2 | Ara-C, ida, amsa, asct | CR |
| 13 | M2 | Ara-C, dauno, amsa, etop, mito | CR |
| 14 | M2 | Ara-C, ida, amsa, asct | CR |
| 15 | M4 | Ara-C, ida, amsa, etop, mito | CR |
| 16 | M2 | Ara-C, dauno, amsa, etop, mito | PR |
| 17 | M2 | Ara-C, etop, mito | CR |
| 18 | M4 | Ara-C, dauno, asct | CR |
| 19 | M2 | Ara-C, dauno, amsa, asct | CR |
| 20 | M0 | Ara-C, dauno, amsa, asct | PR |
Ida indicates idarubicin; amsa, amsacrine; asct, autologous stem cell transplantation, including conditioning regimen with busulfan and cyclophosphamide; etop, etoposide; mito, mitoxantrone; dauno, daunorubicin; CR, complete remission; PR, partial remission; and NR, no response.